<DOC>
	<DOCNO>NCT02183610</DOCNO>
	<brief_summary>To determine basic pharmacokinetics BI 1356 BS , metabolite CD 1750 XX radioactivity include excretion mass balance , excretion pathway metabolism follow intravenous oral administration [ 14C ] BI 1356 BS</brief_summary>
	<brief_title>Investigation Metabolism Pharmacokinetics 10 mg 14C BI 1356 Administered Orally Compared 5 mg 14C BI 1356 Administered Intravenously Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age &gt; =30 Age &lt; =60 year BMI &gt; =18.5 BMI &lt; =29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good clinical practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke stay trial centre Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) ; Male subject must agree minimize risk female partner become pregnant dose day 3 month completion study . Acceptable method contraception male volunteer include vasectomy less 3 month prior dose , barrier contraception medically accept contraceptive method . For female partner male volunteer , acceptable method contraception include intrauterine device , tubal ligation , hormonal contraceptive since least two month diaphragm spermicide Exclusion criterion specific study : Veins unsuitable infusion blood sample PR interval &gt; 220 m QRS interval &gt; 120 m Female gender</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>